Journal Watch · Frontiers in Immunology · 2026

Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.

Active surveillance and personalized management strategies, based on risk stratification and multimodal therapeutic approaches, are essential to optimize outcomes in transplant recipients affected with KS.

Mularoni A, Cona A, Piazza C et al.Frontiers in Immunology3 min readPharma relevance 75/100

DOI: 10.3389/fimmu.2026.1698179PMID: 41953036Study type: research study

TL;DR

Active surveillance and personalized management strategies, based on risk stratification and multimodal therapeutic approaches, are essential to optimize outcomes in transplant recipients affected with KS.

Key findings

  • KS usually presents with cutaneous lesions, however post-transplant KS is characterized by visceral and/or lymph node involvement, frequently in absence of cutaneous lesions, underlying the challenges associated with KS diagnosis in SOT and the need of high clinician suspicion.
  • The mainstay of post-transplant KS management is reduction of immunosuppression, along with conversion to mTOR inhibitors, while in visceral forms chemotherapy with liposomal doxorubicin is usually the first choice.
  • Active surveillance and personalized management strategies, based on risk stratification and multimodal therapeutic approaches, are essential to optimize outcomes in transplant recipients affected with KS.

What they did

Both latent and lytic phases of the HHV-8/KSHV life cycle play crucial role in the pathogenesis, influencing oncogenesis, immune evasion, and inflammasome activation. KS can be the result of reactivation of HHV-8/KSHV latent infection in the immunosuppressed recipient or be the consequence of a primary infection (either donor- or non-donor-derived), the latter possibly associated with a more aggressive clinical course.

Full abstract (original)

Background: Kaposi's sarcoma (KS) is one of the most frequent malignancies observed in solid organ transplant (SOT) recipients, and it is associated with human herpes virus 8/Kaposi's sarcoma-associated herpesvirus (HHV-8/KSHV) infection. The incidence varies according to the prevalence of HHV-8/KSHV in the population, the intensity of the immunosuppression and serological status of organ donor and recipient.

What they did: Both latent and lytic phases of the HHV-8/KSHV life cycle play crucial role in the pathogenesis, influencing oncogenesis, immune evasion, and inflammasome activation. KS can be the result of reactivation of HHV-8/KSHV latent infection in the immunosuppressed recipient or be the consequence of a primary infection (either donor- or non-donor-derived), the latter possibly associated with a more aggressive clinical course.

Results & conclusions: KS usually presents with cutaneous lesions, however post-transplant KS is characterized by visceral and/or lymph node involvement, frequently in absence of cutaneous lesions, underlying the challenges associated with KS diagnosis in SOT and the need of high clinician suspicion. The mainstay of post-transplant KS management is reduction of immunosuppression, along with conversion to mTOR inhibitors, while in visceral forms chemotherapy with liposomal doxorubicin is usually the first choice. Active surveillance and personalized management strategies, based on risk stratification and multimodal therapeutic approaches, are essential to optimize outcomes in transplant recipients affected with KS.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1698179 · PubMed 41953036.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Active surveillance and personalized management strategies, based on risk stratification and multimodal therapeutic approaches, are essential to optimize outcomes in transplant recipients affected with KS.

What type of study is this?

It is a research study, published in Frontiers in Immunology in 2026. Both latent and lytic phases of the HHV-8/KSHV life cycle play crucial role in the pathogenesis, influencing oncogenesis, immune evasion, and inflammasome activation.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1698179. PubMed ID: 41953036. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Mularoni A, Cona A, Piazza C et al.. Kaposi sarcoma in solid organ transplant recipients: updates in epidemiology, diagnosis, treatment and prevention.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1698179.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/kaposi-sarcoma-in-solid-organ-transplant-recipients-updates-in-epidemiol-698179/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides